Triadimefon


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0001755 Neural crest cell migration Decreases phenotype PMID:26238599
GO:0001843 Neural tube closure Decreases phenotype PMID:28263823
GO:0030325 Adrenal gland development Affects phenotype PMID:34508824
GO:0030520 Intracellular estrogen receptor signaling pathway Affects phenotype PMID:39365753
GO:0030521 Androgen receptor signaling pathway Affects phenotype PMID:39365753
GO:0032341 Aldosterone metabolic process Affects phenotype PMID:34508824
GO:0035934 Corticosterone secretion Affects phenotype PMID:34508824
GO:0045444 Fat cell differentiation Increases phenotype PMID:36951524
GO:0048863 Stem cell differentiation Decreases phenotype PMID:32205227
GO:0050810 Regulation of steroid biosynthetic process Affects phenotype PMID:26781511
GO:0055007 Cardiac muscle cell differentiation Decreases phenotype PMID:29337257
GO:0060037 Pharyngeal system development Decreases phenotype PMID:28263823
GO:0140042 Lipid droplet formation Increases phenotype PMID:36951524

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.